Iterum Therapeutics PLC expected to post a loss of 20 cents a share - Earnings Preview

Iterum Therapeutics

12/11/2024 13:58

* Iterum Therapeutics PLC  ITRM.OQ   ITRM.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 14 for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Iterum Therapeutics PLC
is for
a loss of 20 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Iterum
Therapeutics PLC is $7.50​, above​ its last closing price
of $1.39. ​​​

This summary was machine generated November 12 at 13:58 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)